Is that why Aerpio Pharmaceuticals (Nasdaq: ARPO) stock plunged in the AH session?


    Aerpio Pharmaceuticals, (Nasdaq: ARPO), the stock dipped -40.89% to $1.33 in the After-market session, as Razuprotafib met its primary efficacy endpoint at 28 days in Aerpio’s double-blind Phase 2 trial in patients with elevated intraocular pressure associated with open-angle glaucoma and ocular hypertension.

    Compared to the monotherapy group, razuprotafib did not show any statistically significant change in IOP at Day 28 when tested on the two groups separately.

    Top 5 EV Tech Stocks to Buy for 2023

    The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

    Click Here to Download the FREE Report.


    The study aimed to assess the safety and efficacy of topical ocular formulations of razuprotafib as an adjunct to the standard of care latanoprost.

    A total of 194 patients underwent a 28-day washout cycle. It was randomized to undergo 0.005 percent latanoprost ophthalmic solution once daily with placebo-based adjunctive treatment, 40 mg/ml razuprotafib once daily, or 40 mg/ml razuprotafib twice daily, in a 1:1:1 fashion. The key endpoint of the analysis by latanoprost monotherapy groups was a mean diurnal IOP for the treatment of razuprotafib at 28 days.


    Please enter your comment!
    Please enter your name here